Skip to main content

Advertisement

Table 1 Baseline characteristics of the study groupsa

From: Randomized supplementation of 4000 IU vitamin D3 daily vs placebo on the prevalence of anemia in advanced heart failure: the EVITA trial

Characteristics Vitamin D 4000 IU (n = 85) Placebo (n = 87) P-Value
Females (%) 12.9 21.8 0.12
Age (years) 56 (49–61) 54 (47–59) 0.09
Anemic subjectsb (%) 17.2 10.6 0.19
BMI (kg/m2) 28.4 (25.0–31.4) 28.1 (25.7–32.2) 0.59
NYHA (%)
 Class II 77.6 71.3 0.34
 Class III 22.4 28.7 0.34
 LVEF (%) 30.0 (23.5–35.0) 28.0 (24.0–35.0) 0.96
 LVED (mm) 66.0 (59.0–73.0) 66.0 (60.0–75.0) 0.97
Primary Disease (%)
 Dilated cardiomyopathy 38.8 50.6 0.12
 Coronary heart disease 57.6 42.5 0.05
 Others 3.5 6.9 0.32
Comorbidities (%)
 Diabetes 28.2 16.1 0.06
 Arterial hypertension 25.9 29.9 0.56
 Renal insufficiency 10.6 8.0 0.57
Drug therapy (%)
 Loop diuretic 82.4 86.2 0.49
 Thiazide diuretic 25.9 31.0 0.45
 Aldosterone antagonist 81.2 86.2 0.37
 ACE- inhibitor 72.9 71.3 0.81
 AT II blocker 29.4 36.8 0.31
 Beta-blocker 96.5 97.7 0.63
 Digoxin 31.8 40.2 0.25
 Antiarrhythmic drug 24.7 28.7 0.55
 Lipid-lowering drug 57.6 54.0 0.63
 Calcium channel blocker 3.5 3.4 0.98
 Vitamin D supplement 0.0 0.0 > 0.999
Vitamin D metabolites
 25OHD (nmol/L) 30.7 (22.0–46.6) 34.4 (26.7–45.9) 0.37
 1,25(OH)2D (pmol/L)c 81.6 (60.8–100.9) 87.7 (65.2–104.8) 0.18
Hematological parameters
 Hemoglobin (g/dL) 14.2 ± 1.6 14.2 ± 1.5 0.97
 Hematocrit (%) 42.2 ± 4.9 42.2 ± 4.2 0.93
 Leukocytes (109/L) 8.1 (6.8–9.6) 7.7 (6.2–9.6) 0.37
 Erythrocytes (1012/L) 4.7 (4.4–5.0) 4.6 (4.3–4.9) 0.42
 MCV (μm3) 90.6 (88.1–93.4) 92.9 (90.1–95.6) 0.01
 MCH (pg Hb/red blood cell) 30.7 ± 2.0 31.2 ± 2.5 0.10
 MCHC (g/L) 33.6 (33.0–34.8) 33.9 (33.0–34.7) 0.87
 RDW (%) 12.7 (11.9–13.5) 12.5 (11.9–13.2) 0.32
Additional parameters
 eGFR values
 ≥ 60 mL/min/1.73 m2 (%) 69.8 73.6 0.6
 < 60 mL/min/1.73 m2 (%) 30.2 26.4 0.62
 CRP (mg/dL)d 0.24 (0.10–0.69) 0.21 (0.09–0.40) 0.41
 BNP (pg/mL)e 270 (164–515) 248 (117–614) 0.96
 Calcium (mmol/L) 2.39 ± 0.12 2.38 ± 0.11 0.70
  1. BNP brain natriuretic peptide, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, eGFR estimated globular filtration rate, LVEF left ventricular ejection fraction, LVED left ventricular end-diastolic diameter, MCH mean corpuscular hemoglobin, MCV mean corpuscular volume, RDW red blood cell distribution width
  2. amedian and interquartile range, mean and SD, or percentage of observations, when appropriate
  3. bHemoglobin < 12.0 g/dL in females and < 13.0 g/dL in males
  4. cdata are based on 161 patients
  5. ddata are based on 155 patients
  6. edata are based on 115 patients